The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model.

Alzheimers Dement 2017 01 29;13(1):8-19. Epub 2016 Aug 29.

Department of Biostatistics, Washington University in St Louis, St Louis, MO, USA.

Introduction: The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) trial is an adaptive platform trial testing multiple drugs to slow or prevent the progression of Alzheimer's disease in autosomal dominant Alzheimer's disease (ADAD) families. With completion of enrollment of the first two drug arms, the DIAN-TU now plans to add new drugs to the platform, designated as the Next Generation (NexGen) prevention trial.

Methods: In collaboration with ADAD families, philanthropic organizations, academic leaders, the DIAN-TU Pharma Consortium, the National Institutes of Health, and regulatory colleagues, the DIAN-TU developed innovative clinical study designs for the DIAN-TU NexGen prevention trial.

Results: Our expanded trial toolbox consists of a disease progression model for ADAD, primary end point DIAN-TU cognitive performance composite, biomarker development, self-administered cognitive assessments, adaptive dose adjustments, and blinded data collection through the last participant completion.

Conclusion: These steps represent elements to improve efficacy of the adaptive platform trial and a continued effort to optimize prevention and treatment trials in ADAD.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jalz.2016.07.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5218895PMC
January 2017
72 Reads

Publication Analysis

Top Keywords

progression model
8
disease progression
8
adaptive platform
8
alzheimer's disease
8
nexgen prevention
8
adad families
8
trial adaptive
8
platform trial
8
dian-tu
7
trial
5
developed innovative
4
innovative clinical
4
dian-tu developed
4
health regulatory
4
regulatory colleagues
4
colleagues dian-tu
4
clinical study
4
prevention treatment
4
trialresults expanded
4
expanded trial
4

Similar Publications